GlassScriptPhysician profile
Deborah A Kendrick
NPI 1811310154
$1,781.73
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $440 · 2021: $382 · 2022: $433 · 2023: $65.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $457.90 | 2019-2022 | |
| Roche Diagnostics Corporation | $139.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $114.43 | 2019-2020 | |
| Organon LLC | $114.29 | 2021-2022 | |
| Coopersurgical, INC. | $104.05 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $96.66 | 2019 | |
| Sage Therapeutics, LLC | $96.65 | 2020 | |
| Gilead Sciences, INC. | $95.16 | 2019 | |
| Exeltis, USA INC. | $58.50 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $57.60 | 2020-2021 | |
| Avion Pharmaceuticals | $53.65 | 2020-2022 | |
| Agile Therapeutics, INC. | $53.18 | 2021-2022 | |
| Evofem Biosciences, INC. | $48.61 | 2021-2022 | |
| Novo Nordisk INC | $46.40 | 2023 | Ozempic, Rybelsus |
| Myovant Sciences INC. | $45.82 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.85 | 2022 | |
| Hologic Sales and Service, LLC | $33.09 | 2019-2020 | |
| Mission Pharmacal Company | $28.04 | 2020 | |
| Daiichi Sankyo INC. | $23.34 | 2019 | |
| Sumitomo Pharma America, INC. | $18.62 | 2023 | Gemtesa |
| Therapeuticsmd, INC. | $17.49 | 2022 | |
| Lupin INC. | $17.09 | 2020 | |
| Mayne Pharma Commercial LLC | $15.57 | 2022 | |
| Allergan, INC. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Kendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.